Plain-English translation of NCT06777030 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Read our Pancreatic Cancer research guide →Researchers are studying tiny particles called exosomes that are released by pancreatic cancer cells into the bloodstream and urine. By examining these particles in blood, urine, and tissue samples from people with pancreatic cancer, the team hopes to find new ways to detect and understand this disease better.
Pancreatic cancer is hard to catch early because there aren't reliable markers doctors can easily test for. This research aims to discover whether these tiny particles could serve as new biomarkers — simple warning signs that show up in blood or urine tests — to help identify pancreatic cancer sooner.
You likely qualify if…
You likely don't qualify if…
You will have blood and urine samples collected, and a small tissue sample taken during an endoscopic procedure (a camera exam that doctors may already be doing as part of your regular care). The study is a one-time visit at a single medical center in Bologna, Italy. Your samples will be analyzed in the laboratory to study the exosomes and their contents.
AI-generated summary from trial data · Aug 11, 2026 · Not medical advice
Italy
Enrollment target
~60 participants
Started
May 2022
Primary completion
December 2026
Age range
18 Years and older
Last updated on clinicaltrials.gov in January 2025.
Reach out to the team running this trial. Response times vary — some teams are faster than others.
Central contact
Leonardo Henry Umberto Eusebi, MD
IRCCS Azienda Ospedaliero-Universitaria di Bologna
Tell us you're interested and we'll help connect you with the research team. We'll walk you through what to expect first — no email needed to get started.